Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Civitas Therapeutics

http://www.civitastherapeutics.com

Latest From Civitas Therapeutics

Anatomy Of A Biotech Company: Acorda Gets Dressed For A Second Act

Acorda's rise, fall, and attempt to rise again is a snapshot of the life of a biotech. The company reached the commercial-stage pinnacle with Ampyra, only to eventually see it fall away to patent challenges. Now, after big staff cuts, the company is hoping to prevail in the commercial market again, this time with Inbrija.

Leadership Companies

Anatomy Of A Biotech Company: Acorda Gets Dressed For A Second Act

Acorda's rise, fall, and attempt to rise again is a snapshot of the life of a biotech. The company reached the commercial-stage pinnacle with Ampyra, only to eventually see it fall away to patent challenges. Now, after big staff cuts, the company is hoping to prevail in the commercial market again, this time with Inbrija.

Commercial Companies

Keeping Track: US FDA Refuses To File Acorda, SteadyMed NDAs

Issues involving inspectional readiness and the drug master production record cited in agency's refusal to review Acorda's Inbrija in Parkinson's disease; SteadyMed faces request for additional design verification and validation testing for drug/device combo Trevyent in pulmonary arterial hypertension.

United States FDA

Acorda Investor Scopia Seeks Big Return From Sale Of The Company

Citing recent deals, hedge fund Scopia encouraged Acorda's board on Aug. 7 to pursue a sale, but the company believes its new strategy focused on Parkinson's disease is best for shareholders.

Business Strategies M & A
See All

Company Information

UsernamePublicRestriction

Register